Results 141 to 150 of about 530,731 (290)

SENIOR‐IPI: An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent

British Journal of Haematology, EarlyView.
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois, Fanny Cherblanc, Aurelien Belot, Lucie Oberic, Hervé Ghesquières, Corinne Haioun, Hervé Tilly, Jean‐Philippe Jais, Fabrice Jardin   +8 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Discovery and development of a bispecific antibody for the treatment of hemophilia. [PDF]

Proc Natl Acad Sci U S A
Pao W.
europepmc   +1 more source

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy. [PDF]

Blood Adv
Le Henaff JR, Le Guennec L, Schiro P, Bihan K, Gasnault J, Stankoff B, Taoufik Y, Treiner E, Bensoussan D, Lhomme S, L'Honneur AS, Bonneville F, Shor N, Pourcher V, Pignolet B, Lievin B, Javaux C, Le Guen J, Brissot E, Limouzin PA, Richaud C, Lioure B, Wirth T, Petitgas P, Herbel S, Coustillères F, Rusu EC, Maerten L, Perrot A, Sommet A, Roos-Weil D, Lafaurie M, Weiss N, Martin-Blondel G, THEOREM Study Group.   +34 more
europepmc   +1 more source

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma. [PDF]

J Transl Med
Prakash N, Hörner S, Hagelstein I, Keller J, Wang K, Jung G, Salih HR, Lutz MS.   +7 more
europepmc   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma. [PDF]

Blood Adv
Zhang M, Leong WF, Huo J, Xian Ngoh EZ, Loh H, Chen Q, Toh SHM, De Mel S, Ooi M, Soekojo C, Chng WJ, Yang Y, Lam KP, Xu S.   +13 more
europepmc   +1 more source

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation. [PDF]

Front Immunol
Li Y, Li Y, Huang R, San ZQ, Ye JF.
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source